PEBC Part I (MCQ) · Competency 1A Clinical Care (about 50% of Part I)
Heart failure, atrial fibrillation, coronary disease and anticoagulation produce some of the highest-stakes Part I items: drug selection, DOAC dosing, warfarin interactions and secondary prevention, with Canadian (CCS, Thrombosis Canada) guidance and product monographs.
1A Clinical Care3 min read7 sections
Checked against the CCS/CHFS heart failure guidelines (2017 and 2021 update); 2020 CCS/CHRS AF guidelines; 2018 CCS/CAIC antiplatelet update; Thrombosis Canada clinical guides (2024); Health Canada product monographs; checked 13 Oct 2026. Not affiliated with or endorsed by The Pharmacy Examining Board of Canada (PEBC).
Expect case sets: a discharge regimen to optimise, a DOAC dose to check against weight, age and kidney function, or a warfarin patient started on an interacting antibiotic or amiodarone.
Titrate beta-blockers slowly; fatigue early is common; take carvedilol with food.
Hold MRA if potassium exceeds about 5.5 mmol/L; recheck promptly.
SGLT2 inhibitors reduce HF hospitalization in HFrEF and HFpEF, with or without diabetes.
Daily weights: report a gain of about 2 kg over 2 days.
Every note. Every question. One pass.
5 more sections of this note are part of Premium.
From about C$16.58/mo on the Until-you-pass pass (12 months)
Educational practice material for exam preparation only. Not medical advice and not a substitute for current product monographs, clinical guidelines or professional judgement. Questions have not yet been reviewed by a licensed pharmacist.
